Dive Brief:

潜水简介：

GSK says it owns seven patents that “provide the foundation” for Moderna’s messenger RNA vaccine portfolio, and is now suing the biotechnology company for infringement.

葛兰素史克表示，它拥有7项专利，为Moderna的信使RNA疫苗组合“奠定了基础”，目前正在起诉这家生物技术公司侵权。

At issue is the work of a team led by Christian Mandl, who was a top official in the vaccines unit at Novartis between 2008 and 2015. According to the lawsuit, Mandl’s team discovered new formulations and methods of preparing mRNA vaccines, overcoming hurdles that had long prevented development of successful shots using the technology..

争论的焦点是克里斯蒂安·曼德尔（ChristianMandl）领导的团队的工作，他在2008年至2015年间是诺华疫苗部门的高级官员。根据诉讼，Mandl的团队发现了制备mRNA疫苗的新配方和方法，克服了长期以来阻碍使用该技术开发成功疫苗的障碍。。

The team filed for patents on their work in 2010. GSK then acquired that intellectual property when it took over much of Novartis’ vaccines business in 2015. Now, GSK is saying Moderna’s COVID-19 vaccines infringe those patents and is seeking damages. A Moderna spokesperson said the company is aware of the suit and will defend itself against the claims..

该团队于2010年就其工作申请了专利。2015年，葛兰素史克（GSK）接管了诺华（Novartis）的大部分疫苗业务，获得了这一知识产权。现在，葛兰素史克表示，Moderna的新型冠状病毒肺炎疫苗侵犯了这些专利，正在寻求赔偿。摩德纳的一位发言人表示，该公司知道这起诉讼，并将针对这些指控进行辩护。。

Dive Insight:

潜水洞察：

Moderna, along with rivals Pfizer and BioNTech, achieved an astonishing public health success by developing an mRNA vaccine to fight the COVID-19 pandemic in less than a year. The companies also earned billions of dollars, sparking a series of legal battles over the patents involved.

Moderna与竞争对手辉瑞（Pfizer）和BioNTech（BioNTech）一起，在不到一年的时间内开发了一种mRNA疫苗来抗击新型冠状病毒（COVID-19）大流行，取得了惊人的公共卫生成功。这些公司还赚取了数十亿美元，引发了一系列有关专利的法律诉讼。

Moderna sparred with the U.S. government over intellectual property claims early in the pandemic. In February 2022, Arbutus Biopharma and Genevant Sciences sued Moderna over patents related to the delivery of mRNA shots. Weeks later, Alnylam Pharmaceuticals sued both Moderna and Pfizer, claiming that the companies violated an Alnylam patent on lipid nanoparticle technology..

在疫情早期，摩德纳就知识产权主张与美国政府发生了争执。2022年2月，杨梅生物制药公司（Arbutus Biopharma）和Genevant Sciences就与mRNA注射相关的专利提起诉讼。几周后，Alnylam Pharmaceuticals起诉了Moderna和辉瑞，声称这两家公司违反了Alnylam关于脂质纳米粒子技术的专利。。

The legal battles didn’t stop there. Another mRNA specialist, CureVac, sued BioNTech in July 2022. The following month, Moderna sued Pfizer and BioNTech, which then evened the score a year later by asking the U.S. government to dismiss some of Moderna’s patents.

法律斗争并没有就此停止。另一位mRNA专家CureVac于2022年7月起诉BioNTech。接下来的一个月，Moderna起诉了辉瑞（Pfizer）和BioNTech（BioNTech），一年后，辉瑞和BioNTech要求美国政府驳回Moderna的一些专利，从而使比分持平。

Earlier this year, GSK also sued Pfizer and BioNTech, alleging infringement on different patents stemming from the work of Mandl’s team and former Novartis researcher, Andrew Geall.

今年早些时候，葛兰素史克（GSK）还起诉了辉瑞（Pfizer）和生物技术（BioNTech），指控Mandl团队和诺华（Novartis）前研究员安德鲁·吉尔（AndrewGeall）的工作侵犯了不同的专利。

In the latest lawsuit, filed in federal court in Delaware, GSK says Moderna could not have succeeded in the lightning-quick development of its COVID-19 vaccine without the work of Mandl’s team.

在特拉华州联邦法院提交的最新诉讼中，葛兰素史克表示，如果没有曼德尔团队的努力，摩德纳不可能在其新型冠状病毒疫苗的闪电般快速开发中取得成功。

“Moderna has repeatedly touted the speed at which it produced its original Spikevax vaccine and was later able to modify it to address new viral strains,” GSK said. “But Moderna has consistently failed to acknowledge how it applied the Mandl team’s revolutionary platform to do so.”

葛兰素史克表示：“Moderna一再吹嘘其原始Spikevax疫苗的生产速度，后来能够对其进行改进以应对新的病毒株。”。“但Moderna一直没有承认它是如何应用Mandl团队的革命性平台来做到这一点的。”

GSK is asking a jury to award unspecified damages and a licensing fee for its patents. It’s also seeking to be reimbursed for attorney fees and costs incurred in the lawsuit.

葛兰素史克（GSK）要求陪审团裁定其专利的未指明损害赔偿金和许可费。它还寻求报销律师费和诉讼费用。